CANY
ITCI

Caxton Associates (New York)’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Caxton Associates (New York)’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-14,591
Closed -$893K – 782
2022
Q1 		$893K Buy
+14,591
New +$758K 0.07% 124

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Caxton Associates (New York)'s ITCI Position: Q2 2022 in Review

Caxton Associates (New York) sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2022, closing a stake of 14,591 shares — an estimated $893K sold.

Caxton Associates (New York) first reported a position in ITCI in Q1 2022 and held it in 1 quarter. The position peaked at $893K in Q1 2022. 266 funds tracked by Wall St. Rank hold ITCI as of Q2 2022.

  • Caxton Associates (New York) reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2022 after selling out during the quarter.
  • Caxton Associates (New York) sold 14,591 Intra-Cellular Therapies Inc. shares in Q2 2022, an estimated $893K.
  • Caxton Associates (New York) first reported a position in Intra-Cellular Therapies Inc. in Q1 2022 and held it in 1 quarter.
  • Caxton Associates (New York)'s Intra-Cellular Therapies Inc. position peaked at $893K in Q1 2022.
  • 266 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2022.

Based on Caxton Associates (New York)'s 13F filing for Q2 2022, filed 15 Aug 2022.